Zambon S.p.A., an international pharmaceutical company strongly committed to the central nervous system (CNS) therapeutic area, and Valeo Pharma Inc., a specialty pharmaceutical company dedicated to commercializing innovative prescription products in Canada, today announce the approval of safinamide for thetreatment of Parkinson’s Disease in Canada.
Roberto Tascione, CEO of Zambon said “The approval of safinamide in Canada is a stepforward for patients who need new treatment options for Parkinson’s Disease. Our mission is to make this medication available to as many PD patients worldwide as possible.”
For more info:
https://www.zambon.com/sites/corporate/files/news/files/2019-01/Comunicato%20stampa%20Valeo_FINAL%20version%202.pdf